[Skip to the reading](https://peptidesandprosecco.com/glp-1-medicines#reading) 

[Peptides and Prosecco](/) 

[What did my friend mean?](/#what-i-heard) 
[What are GLP-1 medicines?](/glp-1-medicines) 
[What would I ask a clinician?](/care-questions) 

[Home](/) / GLP-1 medicines

# Put the GLP-1 chatter beside the actual evidence

Semaglutide and tirzepatide often get mentioned in the same breath. They’re different medicines, and each has FDA-approved products for type 2 diabetes and for weight management in particular groups. The product matters: an approval for one use doesn’t cover every reason someone might want it.

## The appetite part has a real explanation

![At a relaxed outdoor get-together, an adult smiles and waves away a second helping of salad.](/prosecco-stoop-67c4ce88067d/ordinary-appetite.webp)

A smile and a wave say that the second helping can wait.

GLP-1 is a gut hormone that helps regulate appetite and blood sugar. Semaglutide copies that signal. Tirzepatide also activates the receiving points for a second gut hormone, called GIP, as the [Zepbound (tirzepatide) label explains](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b) . Two targets don’t tell us which medicine fits your health.

That appetite effect is part of how these medicines work. I don’t read someone’s changed appetite as a sudden improvement in willpower. I’d rather talk about what they need from care and what the trade-offs might be. The common side effects are mostly digestive: constipation, nausea, diarrhea and vomiting.

## The trials mean something, within their boundaries

A [semaglutide trial in adults without diabetes](https://pubmed.ncbi.nlm.nih.gov/33567185/) found more weight loss than placebo, a comparison treatment without the active medicine. Participants had obesity, or overweight with a related health problem. Both groups received lifestyle support, so that support belongs in the story too.

A [tirzepatide trial in adults without diabetes](https://pubmed.ncbi.nlm.nih.gov/35658024/) also found greater weight loss than placebo. These are useful findings about the people studied. They can’t tell a friend what result to expect or decide which product is suitable for them.

## Leave space for the unglamorous questions

I’d leave room in the appointment for more than the hoped-for result. What could make the medicine unsuitable? Which symptoms need attention, and who handles follow-up? Getting those answers is part of understanding the treatment.

## The cautions are part of the story

The [Wegovy (semaglutide) label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b) has a boxed warning about tumors in the thyroid’s C cells seen in rodents. Whether these medicines cause those tumors in people is unknown. The label rules it out with a personal or family history of medullary thyroid cancer, a rare thyroid cancer, or multiple endocrine neoplasia syndrome type 2, an inherited condition that can cause tumors. Zepbound has the same exclusions.

A familiar ingredient name doesn’t make a compounded preparation an approved product. [Compounded medicines are not FDA-approved](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers) . A licensed U.S. clinician can assess your health and discuss an approved option where appropriate. The [care questions](/care-questions) help get that conversation ready without picking a treatment for you.

[ Questions for an appointment](/care-questions) [ See the sources](/references) 

I keep this a guide for the questions that linger; it is not a clinic, pharmacy or seller.

[BPC-157 and GHK-Cu](/bpc-157-and-ghk-cu) [NAD+ and PT-141](/nad-and-pt-141) [References](/references) [About](/about) [Contact](/contact) 

© 2026 Peptides and Prosecco